Study Summary
This trial is testing a new cancer treatment for people with melanoma that has spread to the brain.
- Metastatic Melanoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: 1 year
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Lifileucel (LN-144)
1 of 2
Participants with Melanoma Brain Metastases
1 of 2
Experimental Treatment
10 Total Participants · 2 Treatment Groups
Primary Treatment: Lifileucel (LN-144) · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there any open spots remaining in this study?
"Affirmative, according to the information present on clinicaltrials.gov this trial is actively searching for eligible applicants. It initially went live on November 25th 2022 and was updated most recently on the 28th of that same month. 10 patients need to be identified from 1 medical centre." - Anonymous Online Contributor
What is the approximate number of participants for this research project?
"Affirmative, clinicaltrials.gov data indicates that this research is in search of volunteers. This trial was first posted on November 25th 2022 and had its most recent update a few days later on the 28th. 10 participants are needed from one study centre for enrollment into the program." - Anonymous Online Contributor
Has Lifileucel (LN-144) obtained regulatory clearance from the FDA?
"Our analysis at Power has placed the safety of Lifileucel (LN-144) at 1, as this Phase 1 trial only carries a modicum of data backing its efficacy and security." - Anonymous Online Contributor